Portal de Periódicos da CAPES

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

2019; Adis, Springer Healthcare; Volume: 36; Issue: 4 Linguagem: Inglês

10.1007/s12325-019-00910-z

1865-8652

Renato Bassan, Dieter Hoelzer, Xavier Thomas, Pau Montesinos, Jiří Pavlů, Jan McKendrick, Amber Kudlac, Arie Barlev, Beth Barber, Ze Cong,

Lymphoma Diagnosis and Treatment

Despite the poor prognosis for adults with relapsed or refractory (RR) Philadelphia chromosome (Ph)-negative B cell precursor acute lymphoblastic leukemia (ALL), long-term survival is possible and may even be considered as "cure".This study used a Delphi panel approach to explore concepts of cure in RR Ph-negative B cell precursor ALL. Ten European experts in this disease area participated in a survey and face-to-face panel meeting.Findings showed that clinicians conceptualize "cure" as a combination of three broad treatment outcomes that vary depending on the treatment stage: complete remission early in treatment (1-3 months) indicates initial success; eradicating cancer cells (minimal residual disease negative status) consolidates the early clinical response; leukemia-free survival is required in the long term.Although such terminology remains contested, clinicians would begin considering "cure" as early as 2 years provided the patient is off therapy, with most considering the term applicable by the third year.Amgen Inc.